Eli Lilly Slashes German Plant Investment by Half

Eli Lilly has announced a substantial reduction in its investment for a major manufacturing facility in Alzey, Rhineland-Palatinate, Germany. The initial plan of €2.3 billion has been cut by 50%, significantly impacting Germany's industrial development goals. This decision follows criticism from Eli Lilly CEO Dave Ricks regarding Germany's proposed healthcare cost-cutting legislation.

Ricks described the legislation as a "terrible signal to the industry" and warned that Germany could fall behind other European markets in supporting pharmaceutical companies. The new law, proposed by Health Minister Nina Warken, aims to control rising costs by demanding higher discounts and stricter price frameworks from pharmaceutical firms.

As a consequence, Eli Lilly is redirecting over a billion euros, potentially to Pennsylvania in the US or another international location. German competitor Boehringer Ingelheim is also canceling over €900 million in local investments due to similar opposition to the government's plans.

Despite the budget cuts, the Alzey facility is still expected to begin operations in 2027. However, its capacity will be considerably reduced, and the workforce projection has been halved from 1,000 to 500 employees. Ricks indicated that while Europe remains an option, the US market appears more attractive under the current circumstances.